WO1999029705A3 - Sialyl lewis x and sialyl lewis a glycomimetics - Google Patents

Sialyl lewis x and sialyl lewis a glycomimetics Download PDF

Info

Publication number
WO1999029705A3
WO1999029705A3 PCT/US1998/025783 US9825783W WO9929705A3 WO 1999029705 A3 WO1999029705 A3 WO 1999029705A3 US 9825783 W US9825783 W US 9825783W WO 9929705 A3 WO9929705 A3 WO 9929705A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
sialyl lewis
glycomimetics
compounds
useful
Prior art date
Application number
PCT/US1998/025783
Other languages
French (fr)
Other versions
WO1999029705A2 (en
WO1999029705A9 (en
Inventor
Mark B Anderson
Yoshiyuki Kobayashi
Kazuhiro Itoh
Kevin R Holme
Jingrong Cui
Peter Fugedi
Csaba F Peto
Li Wang
Harish Vazir
Original Assignee
Glycomed Inc
Sankyo Co
Mark B Anderson
Yoshiyuki Kobayashi
Kazuhiro Itoh
Kevin R Holme
Jingrong Cui
Peter Fugedi
Csaba F Peto
Li Wang
Harish Vazir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycomed Inc, Sankyo Co, Mark B Anderson, Yoshiyuki Kobayashi, Kazuhiro Itoh, Kevin R Holme, Jingrong Cui, Peter Fugedi, Csaba F Peto, Li Wang, Harish Vazir filed Critical Glycomed Inc
Priority to AU18042/99A priority Critical patent/AU1804299A/en
Publication of WO1999029705A2 publication Critical patent/WO1999029705A2/en
Publication of WO1999029705A3 publication Critical patent/WO1999029705A3/en
Publication of WO1999029705A9 publication Critical patent/WO1999029705A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/10—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a series of compounds in the form of chemically and physiologically stable glycomimics or glycoepitopes that serve to functionally mimic the active features of biologically important oligosaccharides, such as but not limited to sialyl Lewisx (sLex) and sialyl Lewisa (sLea). These structural Glycomimetics have been shown to be useful in the treatment of acute and chronic diseases as well as for the treatment of asthma. These compounds also are useful in the treatment of other selectin-mediated disorders, such as inflammation, cancer, diabetes, obesity, lung vasculitis, cardiac injury, reperfusion injuries, thrombosis, tissue rejection, arthritis, inflammatory bowel disease and pulmonary inflammation.
PCT/US1998/025783 1997-12-08 1998-12-04 Sialyl lewis x and sialyl lewis a glycomimetics WO1999029705A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU18042/99A AU1804299A (en) 1997-12-08 1998-12-04 Sialyl lewis x and sialyl lewis a glycomimetics

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6797197P 1997-12-08 1997-12-08
US60/067,971 1997-12-08

Publications (3)

Publication Number Publication Date
WO1999029705A2 WO1999029705A2 (en) 1999-06-17
WO1999029705A3 true WO1999029705A3 (en) 1999-08-19
WO1999029705A9 WO1999029705A9 (en) 1999-11-11

Family

ID=22079613

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/025783 WO1999029705A2 (en) 1997-12-08 1998-12-04 Sialyl lewis x and sialyl lewis a glycomimetics

Country Status (2)

Country Link
AU (1) AU1804299A (en)
WO (1) WO1999029705A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6461643B2 (en) 1993-04-22 2002-10-08 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
AU2595697A (en) 1996-03-29 1997-10-22 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
ATE295347T1 (en) 1998-07-27 2005-05-15 Emisphere Tech Inc SUBSTANCES AND COMPOSITIONS FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES
US6440929B1 (en) 1998-07-27 2002-08-27 Emisphere Technologies, Inc. Pulmonary delivery of active agents
US7084279B1 (en) 1999-02-11 2006-08-01 Emisphere Technologies Inc. Oxadiazole compounds and compositions for delivering active agents
EP1163209A4 (en) 1999-02-26 2004-12-29 Emisphere Tech Inc Compounds and compositions for delivering active agents
EP1246792B1 (en) 2000-01-13 2014-08-13 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
AU2001288432A1 (en) 2000-09-01 2002-03-22 Icos Corporation Materials and methods to potentiate cancer treatment
US6562995B1 (en) * 2000-12-21 2003-05-13 Beacon Laboratories, Inc. Delta dicarbonyl compounds and methods for using the same
ATE418554T1 (en) 2002-10-24 2009-01-15 Glaxo Group Ltd 1-ACYL-PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS
US7119079B2 (en) * 2003-01-22 2006-10-10 Barbeau Donald L Bioadhesive pharmaceutical compositions
EP1660473A2 (en) 2003-03-24 2006-05-31 Luitpold Pharmaceuticals, Inc. Xanthones, thioxanthones and acridinones as dna-pk inhibitors
US7465798B2 (en) * 2003-11-10 2008-12-16 Wyeth Methods and compositions for selectin inhibition
AU2004288800A1 (en) * 2003-11-10 2005-05-26 Wyeth Methods and compositions for selectin inhibition
EP1577289A1 (en) * 2004-03-18 2005-09-21 Revotar Biopharmaceuticals AG Non-glycosylated/-glycosidic/-peptidic small molecule selectin inhibitors for the treament of inflammatory disorders
ME01541B (en) 2005-04-13 2014-04-20 Astex Therapeutics Ltd Hydroxybenzamide derivatives and their use as in hibitor of hsp90
EP1764095A1 (en) 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Novel nitrocatechol derivatives having selectin ligand activity
EP1764093A1 (en) 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Novel aromatic compounds and their use in medical applications
EP1764096A1 (en) 2005-09-20 2007-03-21 Revotar Biopharmaceuticals AG Novel phloroglucinol derivatives having selectin ligand activity
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
WO2008044029A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
JP5410285B2 (en) 2006-10-12 2014-02-05 アステックス、セラピューティックス、リミテッド Pharmaceutical compounds
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
JP5518478B2 (en) 2006-10-12 2014-06-11 アステックス、セラピューティックス、リミテッド Pharmaceutical compounds
EP2073807A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
US10766970B2 (en) * 2016-07-01 2020-09-08 Wake Forest University Health Sciences Modified carbohydrates, compositions comprising the same, and methods of making and using the same

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0761661A1 (en) * 1995-09-06 1997-03-12 Hoechst Aktiengesellschaft Glycomimetics as selectin antagonists, and anti-inflammatory agents prepared thereof
DE19537334A1 (en) * 1995-10-09 1997-04-10 Hoechst Ag New piperidine carboxylic acid and pyrrolidine carboxylic acid derivs.
WO1997030984A1 (en) * 1996-02-21 1997-08-28 Glycomed Incorporated Sialyl lewisx mimetics containing phenyl backbones

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0761661A1 (en) * 1995-09-06 1997-03-12 Hoechst Aktiengesellschaft Glycomimetics as selectin antagonists, and anti-inflammatory agents prepared thereof
DE19537334A1 (en) * 1995-10-09 1997-04-10 Hoechst Ag New piperidine carboxylic acid and pyrrolidine carboxylic acid derivs.
WO1997030984A1 (en) * 1996-02-21 1997-08-28 Glycomed Incorporated Sialyl lewisx mimetics containing phenyl backbones

Also Published As

Publication number Publication date
AU1804299A (en) 1999-06-28
WO1999029705A2 (en) 1999-06-17
WO1999029705A9 (en) 1999-11-11

Similar Documents

Publication Publication Date Title
WO1999029705A3 (en) Sialyl lewis x and sialyl lewis a glycomimetics
CA2298445A1 (en) Method and compositions for treating late phase allergic reactions and inflammatory diseases
CA2186380A1 (en) Novel carbamates and ureas as modifiers of multi-drug resistance
CA2223776A1 (en) Method of treatment for lung diseases using antisense oligonucleotides
HUP0100069A2 (en) 4(3)substituted-4(3)-aminomethyl-pyran, or -thiopyran-piperidine derivatives, their preparation and their use in the treatment of neurological disorders
BR9814615A (en) Methods and materials for the treatment and prevention of mucosal tissue inflammation
EP0841900A4 (en)
MY114776A (en) Fluoxetine pharmaceutical formulations
EP0797999A3 (en) Formulations of obesity protein
CA2350713A1 (en) Use of biochemical substances for a composition for the prevention and treatment of health conditions caused by constriction of smooth muscle cells in organs of the human body
CA2027831A1 (en) L-sugar laxatives
PT983076E (en) Oxalate-degrading microorganisms or oxalate-degrading enzymes for preventing oxalate related disease
EP0305117A3 (en) 2',3'-dideoxy-3'-fluorothymidine and related compounds for the treatment of adenovirus infections
CA2266608A1 (en) Combination composition in the form of nutritional supplement or pharmaceutical composition for the prevention and therapeutical treatment of degenerative or inflammatory articular disorders
ATE72944T1 (en) FILLING COMPOSITIONS CONTAINING PSYLLIUM.
FR2611274B1 (en) AIDS DETECTION ASSEMBLY, AIDS RISK DETERMINATION METHOD, AND THERAPEUTIC COMPOSITION AGAINST THE SAME
AU2989699A (en) Apparatus to non-invasively measure glucose or other constituents in aqueous humor using infra-red spectroscopy
ATE260639T1 (en) TOPICAL PREPARATIONS CONTAINING SIALYL SUGAR AND THEIR DERIVATIVES
NO984572D0 (en) Use of 2,5-dihydroxybenzenesulfone derivatives for the manufacture of drugs intended for normalization of endothelial function, for the treatment of sexual dysfunction and vascular complications in diabetes, as well as vascular disorders of
WO2000030660A3 (en) Hyperforin as cytostatic agent and hyperforin ointment or cream as application form
WO1999056666A8 (en) The treatment of sexual dysfunction in certain patient groups
CA2206995A1 (en) Use of alkanoyl l-carnitines for the therapeutical treatment of chronic inflammatory bowel diseases
CA2323213A1 (en) Treatment of respiratory disease and otitis media
CA2234936A1 (en) Composition for and treatment of inflammatory bowel disease by colon administration of n-acetylglucosamine
CA2283198A1 (en) Butyrate prodrugs derived from lactic acid

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1-164, DESCRIPTION, REPLACED BY NEW PAGES 1-182; PAGES 165-169, CLAIMS, REPLACED BY NEW PAGES183-187; PAGES 1/13-13/13, DRAWINGS, REPLACED BY NEW PAGES 1/14-14/14; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase